Recombinant Human Anti-C12H18N4O7 Soluble TCR (KIH) (VS-0622-YF6877) (CAT#: VS-0622-YF6877)
Human TCR recognizes C12H18N4O7 peptide (5-(2-oxopropylideneamino)-6-D-ribitylaminouracil) in the context of MR1. Soluble TCR is expressed with Knob-in-hole (KIH) strategy (scTCR-hIgG Knob, scTCR-hIgG Hole). Please note that the activity is not guaranteed.
Specific Inquiry
Specifications
- Host Species
- Human
- Target
- C12H18N4O7
- Epitope
- 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
- MHC
- MR1
- Type
- Soluble TCR (KIH)
- TCR Expression Strategy
- KIH strategy: scTCR-human IgG Knob and scTCR-human IgG Hole can form heterodimer based on Knob-in-hole (KIH) strategy. The soluble TCR contains single chain TCR. With this KIH antibody production strategy, VL/VH will be replaced with Valpha-linker-Vbeta (single chain TCR).
Target
- Alternative Names
- 5-OP-RU; 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-0622-YF6877. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, IHC, FC, IP, IF, Inhib
Application: Neut, IHC, Activ, FuncS, IF, ELISA
Application: ELISA, FC, Inhib, IHC-Fr, WB, IP
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
